Executive Summary
Daiichi Sankyo Co., Ltd. (TSE: 4568) has executed one of the most remarkable strategic transformations in pharmaceutical history—pivoting from a traditional cardiovascular and metabolic drug company into a global oncology powerhouse built on its proprietary antibody-drug conjugate (ADC) technology platform. With a market capitalization of approximately $35–43 billion and nearly 20,000 employees, the company has become the world’s leading ADC developer.
The crown jewel of this transformation is ENHERTU (trastuzumab deruxtecan), a HER2-directed ADC co-developed with AstraZeneca, which has redefined cancer treatment with eight FDA approvals since 2019 and generated JPY 506.8 billion (~$3.4B) in nine-month sales through Q3 FY2025. Daiichi Sankyo’s partnership portfolio now spans over $90 billion in total deal value across collaborations with AstraZeneca (~$13B) and Merck (~$22B), positioning the company as the undisputed global leader in ADC innovation.
1. Company Overview
| Item | Details |
|---|---|
| Company Name | Daiichi Sankyo Co., Ltd. (第一三共株式会社) |
| Founded | September 28, 2005 (merger of Sankyo Co. [est. 1899] and Daiichi Pharmaceutical [est. 1915]) |
| Headquarters | 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan |
| President & CEO | Sunao Manabe |
| Employees | 19,765 (consolidated, March 2025) |
| Stock Exchange | Tokyo Stock Exchange Prime Market (4568) |
| Market Cap | ~¥5.2 trillion (~$35B USD) (February 2026) |
| FY2024 Revenue | ¥1,886.3 billion (~$12.8B USD) |
| FY2025 Revenue Target | ¥2 trillion (~$13.5B USD) |
Corporate History Timeline
| Year | Milestone |
|---|---|
| 1899 | Sankyo Shoten founded; begins manufacturing Taka-Diastase digestive enzyme |
| 1902 | Sankyo produces Adrenalin—Japan’s first domestically manufactured adrenaline |
| 1915 | Arsemin Shokai founded (later becomes Daiichi Pharmaceutical) |
| 2005 | Merger of Sankyo and Daiichi Pharmaceutical creates Daiichi Sankyo |
| 2007 | Full integration completed; Olmesartan (Benicar/Olmetec) drives cardiovascular revenue |
| 2015 | Strategic pivot to oncology announced as Olmesartan faces patent cliff |
| 2019 | $6.9B Enhertu partnership with AstraZeneca; FDA grants first Enhertu approval |
| 2020 | $6B Dato-DXd partnership with AstraZeneca |
| 2023 | $22B mega-deal with Merck for three ADC candidates |
| 2025 | DATROWAY approved by FDA; FY2024 revenue surpasses ¥1.88 trillion |
2. The Enhertu Revolution
ENHERTU (trastuzumab deruxtecan, DS-8201) is widely regarded as the most transformative antibody-drug conjugate in oncology. Built on Daiichi Sankyo’s proprietary DXd ADC technology—which uses a novel topoisomerase I inhibitor payload and a cleavable tetrapeptide-based linker—Enhertu has fundamentally reshaped cancer treatment paradigms.
Enhertu: Key Facts
| Metric | Data |
|---|---|
| Generic Name | Trastuzumab deruxtecan (T-DXd) |
| Target | HER2 (Human Epidermal Growth Factor Receptor 2) |
| First FDA Approval | December 2019 |
| Total FDA Approvals | 8 approvals (as of 2025) |
| FY2025 9M Sales | JPY 506.8 billion (~$3.4B) (+25.3% YoY) |
| Combined FY2025 Sales (DS + AZ) | $4,982 million |
| US In-Market Sales | $2,446 million (FY2025) |
Approved Indications
| Cancer Type | Indication | Significance |
|---|---|---|
| HER2+ Breast Cancer | Previously treated metastatic | Original approval (2019) |
| HER2-low Breast Cancer | Previously treated metastatic | Created an entirely new treatment category |
| HER2-ultralow Breast Cancer | Previously treated metastatic | Further expanded treatable population |
| HER2+ Gastric Cancer | Previously treated advanced | First ADC approved in gastric cancer |
| HER2-mutant NSCLC | Previously treated metastatic | First-in-decade tissue-agnostic approval |
| HER2+ Breast Cancer (1L) | First-line metastatic (DESTINY-Breast09) | Moving to front-line treatment |
Why Enhertu Changed Everything
Enhertu’s breakthrough innovation lies in three key areas:
- Bystander killing effect: The cleavable linker releases the DXd payload inside tumor cells, which then permeates to neighboring cells—even those with low HER2 expression
- High drug-to-antibody ratio (DAR ~8): Approximately twice the payload of earlier ADCs, delivering more potent anti-tumor activity
- HER2-low paradigm shift: Enhertu proved that patients with low HER2 expression—previously considered HER2-negative—could benefit from targeted HER2 therapy, unlocking a massive new patient population
Upcoming Regulatory Milestones
| Trial | Indication | Status |
|---|---|---|
| DESTINY-Breast05 | HER2+ early breast cancer (post-neoadjuvant) | Breakthrough Therapy Designation (Dec 2025); PDUFA July 7, 2026 |
| DESTINY-Breast09 | HER2+ metastatic breast cancer (1L) | Phase 3 completed; superior PFS demonstrated |
| DESTINY-Gastric04 | HER2+ gastric cancer | Phase 3 completed; superior OS demonstrated |
3. ADC Pipeline: The DXd Platform
Daiichi Sankyo’s competitive moat lies in its proprietary DXd ADC technology platform, which enables rapid development of new ADC candidates by swapping targeting antibodies while retaining the proven DXd payload-linker system. The company currently has five DXd-based ADCs in clinical development.
DXd ADC Portfolio Overview
| ADC Candidate | Target | Partner | Status | Key Indication(s) |
|---|---|---|---|---|
| ENHERTU (T-DXd) | HER2 | AstraZeneca | Approved (8 indications) | Breast, gastric, lung cancers |
| DATROWAY (Dato-DXd) | TROP2 | AstraZeneca | Approved (2 indications) | HR+/HER2- breast cancer, EGFR-mutant NSCLC |
| Patritumab deruxtecan (HER3-DXd) | HER3 | Merck | Pivotal trial | EGFR-mutant NSCLC |
| Ifinatamab deruxtecan (I-DXd) | B7-H3 | Merck | Phase 3 (multiple trials) | SCLC, prostate cancer, esophageal cancer |
| Raludotatug deruxtecan (R-DXd) | CDH6 | Merck | Phase 2/3 | Ovarian cancer |
DATROWAY: The Second Pillar
DATROWAY (datopotamab deruxtecan), Daiichi Sankyo’s TROP2-directed ADC, received its first FDA approvals in January 2025 for HR-positive, HER2-negative breast cancer and EGFR-mutated NSCLC. Analysts project it could achieve peak sales of $5.9 billion by 2030. A supplemental BLA for triple-negative breast cancer has been granted Priority Review with FDA action expected in Q2 2026.
Ifinatamab Deruxtecan: The Next-Generation Candidate
Ifinatamab deruxtecan (I-DXd), targeting B7-H3, is currently being evaluated in three Phase 3 trials:
- IDeate-Lung02: Relapsed small cell lung cancer (vs. chemotherapy)
- IDeate-Prostate01: Metastatic castration-resistant prostate cancer (vs. docetaxel)
- IDeate-Esophageal01: Advanced esophageal squamous cell carcinoma
Daiichi Sankyo’s goal is to expand from two approved ADCs to four by 2030, with ifinatamab deruxtecan and raludotatug deruxtecan as the next approval candidates.
4. Global Market Position
ADC Market Leadership
The global antibody-drug conjugate market was valued at $16.14 billion in 2025 and is projected to reach $32.66 billion by 2035 (CAGR ~9.2%). Daiichi Sankyo’s Enhertu alone generated nearly $5 billion in combined sales in FY2025—making it the highest-revenue ADC globally and giving Daiichi Sankyo an estimated 30%+ share of the total ADC market.
Japanese Pharma Competitive Landscape
| Company | FY2024 Revenue | Market Cap | Primary Focus | ADC Presence |
|---|---|---|---|---|
| Takeda | ~¥4.26 trillion | ~$45B | GI, rare diseases, neuroscience | Early-stage ADC programs |
| Daiichi Sankyo | ¥1.89 trillion | ~$35B | Oncology (ADCs) | Global leader: 5 ADC candidates |
| Astellas | ~¥1.6 trillion | ~$18B | Urology, oncology | Limited |
| Eisai | ~¥750B | ~$12B | Neurology (Leqembi), oncology | HER2-ADC collaboration (early) |
Global ADC Competitive Landscape
| Company | Key ADC Product | Target | FY2025 Sales (est.) | Key Indication |
|---|---|---|---|---|
| Daiichi Sankyo / AZ | ENHERTU | HER2 | ~$5.0B | Breast, gastric, lung |
| Daiichi Sankyo / AZ | DATROWAY | TROP2 | Launching | Breast, lung |
| Seagen (Pfizer) | PADCEV | Nectin-4 | ~$4.0B | Urothelial cancer |
| Roche | Kadcyla | HER2 | ~$2.0B | Breast cancer |
| Gilead | Trodelvy | TROP2 | ~$1.5B | Breast, urothelial |
| AbbVie | ELAHERE | FR-alpha | ~$1.0B | Ovarian cancer |
Daiichi Sankyo’s ADC portfolio now represents the largest ADC franchise in the world, with Enhertu surpassing Pfizer’s PADCEV and Roche’s Kadcyla by a significant margin.
5. Financial Analysis
Revenue and Profitability Trend
| Metric | FY2022 | FY2023 | FY2024 | FY2025 (9M) | FY2025 Target |
|---|---|---|---|---|---|
| Revenue (¥B) | 1,044.9 | 1,280.5 | 1,886.3 | 1,533.5 | 2,000.0 |
| Core Operating Profit (¥B) | 137.7 | 152.3 | 312.8 | 249.2 | 350.0 |
| Operating Margin | 13.2% | 11.9% | 16.6% | 16.2% | 17.5% |
| Net Income (¥B) | — | — | 295.8 | — | — |
| Enhertu Sales (¥B) | — | — | — | 506.8 | — |
| YoY Revenue Growth | — | +22.5% | +47.3% | +12.1% | — |
Key Financial Highlights
- FY2024 revenue surged 47.3% YoY to ¥1,886.3 billion—driven by Enhertu growth and the $4 billion Merck upfront payment
- Core operating profit grew 60.2% YoY in FY2024 to ¥312.8 billion
- FY2025 target of ¥2 trillion in revenue would mark a historic milestone for the company
- Enhertu Q3 FY2025 YTD sales reached ¥506.8 billion (+25.3% YoY), on track to exceed ¥650 billion for the full year
- Revenue has nearly doubled in three years from ¥1.04 trillion (FY2022) to ¥1.89 trillion (FY2024)
Revenue by Business Unit (H1 FY2025)
| Business Unit | Revenue (¥B) | YoY Change | Key Drivers |
|---|---|---|---|
| Oncology (US & Europe) | 273.0 | +26.7% | Enhertu growth, DATROWAY launch |
| Japan | 249.9 | +4.3% | Lixiana, Tarlige, DATROWAY, Belsomra |
| Other | — | — | Vaccines, generics, other regions |
The oncology unit’s share of total revenue continues to grow rapidly, reflecting the company’s successful strategic transformation.
6. AstraZeneca Partnership
The Daiichi Sankyo–AstraZeneca collaboration is one of the largest partnerships in pharmaceutical history, spanning two ADC programs with a combined deal value of approximately $13 billion.
Partnership Deal Structure
| Deal | Product | Year | Value | Terms |
|---|---|---|---|---|
| Deal 1 | ENHERTU (T-DXd) | 2019 | Up to $6.9 billion | $1.35B upfront + milestones; 50/50 co-development and profit share (ex-Japan) |
| Deal 2 | DATROWAY (Dato-DXd) | 2020 | Up to $6 billion | $1B upfront + milestones; 50/50 co-development and profit share (ex-Japan) |
Key Partnership Terms
- Global co-development and co-commercialization (excluding Japan, where Daiichi Sankyo retains exclusive rights)
- Equal sharing of development expenses, commercialization costs, and profits
- AstraZeneca’s global oncology commercial infrastructure accelerated Enhertu’s global reach
- Daiichi Sankyo maintains manufacturing control, ensuring quality and supply chain integrity
7. Merck Partnership
In October 2023, Daiichi Sankyo entered a second transformative partnership with Merck & Co., this time for three next-generation DXd ADC candidates in a deal valued at up to $22 billion.
Merck Deal Financial Terms
| Component | Amount |
|---|---|
| Upfront Payment | $4 billion |
| Continuation Payments | $1.5 billion (over 24 months) |
| Sales Milestones | Up to $16.5 billion |
| Total Potential Value | Up to $22 billion |
Three ADCs in the Merck Collaboration
| ADC | Target | Lead Indication | Development Stage |
|---|---|---|---|
| Patritumab deruxtecan (HER3-DXd) | HER3 | EGFR-mutant NSCLC | Pivotal trial |
| Ifinatamab deruxtecan (I-DXd) | B7-H3 | SCLC, prostate, esophageal | Phase 3 (3 trials) |
| Raludotatug deruxtecan (R-DXd) | CDH6 | Ovarian cancer | Phase 2/3 |
Merck reportedly offered the highest valuation among multiple bidders, underscoring the industry’s confidence in Daiichi Sankyo’s DXd platform technology.
8. The Strategic Transformation: From Cardiovascular to Oncology
Daiichi Sankyo’s transformation is one of the most studied pivots in the pharmaceutical industry. The company’s shift from a traditional cardiovascular and metabolic drug company to an oncology-first innovation company is a case study taught at Harvard Business School.
The Transformation Timeline
| Phase | Period | Key Events |
|---|---|---|
| Legacy Era | 2005–2014 | Revenue driven by Olmesartan (Benicar/Olmetec); cardiovascular focus |
| Patent Cliff | 2013–2016 | Olmesartan genericization; global sales declined ~33% |
| Oncology Pivot | 2015–2019 | 2025 Vision: “Global Pharma Innovator with Competitive Advantage in Oncology” |
| ADC Breakthrough | 2019–present | Enhertu approval, AstraZeneca partnership, Merck deal, DATROWAY approval |
The Origin Story: A Bold Scientific Bet
In the early 2000s, Daiichi Sankyo researcher Toshinori Agatsuma proposed redirecting R&D toward antibody-drug conjugate research—at a time when the ADC field was struggling and most industry observers were skeptical about its future. Daiichi Sankyo’s leadership, rooted in a culture of scientific freedom, gave Agatsuma the resources to pursue this vision. That early bet would eventually yield the DXd platform technology that now underpins a multi-billion dollar franchise.
9. Competitive Landscape
ADC Market: The New Battleground
The ADC market has become one of the most competitive spaces in oncology, with over 200 companies and 220+ drug candidates. However, Daiichi Sankyo maintains a commanding lead:
Competitive Positioning Matrix
| Company | ADC Strategy | Key Advantage | Key Risk |
|---|---|---|---|
| Daiichi Sankyo | Platform leader (DXd technology) | 5 ADCs, 2 approved, proven payload/linker | Pipeline concentration risk |
| Pfizer (Seagen) | Acquired Seagen for $43B | PADCEV + ADCETRIS franchise | Integration execution risk |
| AbbVie | ImmunoGen acquisition ($10.1B) | ELAHERE in ovarian cancer | Single product dependency |
| Roche | Pioneer (Kadcyla, Polivy) | Established oncology infrastructure | Older technology, market share erosion |
| Gilead | Trodelvy (TROP2-directed) | First-mover in TROP2 ADC | Competition from DATROWAY |
What Sets Daiichi Sankyo Apart
- Platform approach: Unlike competitors with one or two ADC assets, Daiichi Sankyo has a modular technology platform that enables rapid generation of new ADC candidates
- Partnership model: By partnering with AstraZeneca (commercialization) and Merck (late-stage development), Daiichi Sankyo leverages global infrastructure while retaining IP ownership
- Revenue growth trajectory: 30–40% annual revenue growth projected through 2026, far outpacing peers
- Japan exclusivity: Daiichi Sankyo retains exclusive commercialization rights in Japan for all ADC products, maximizing domestic margins
10. Business Opportunities
For International Partners and Investors
| Opportunity | Details | Potential |
|---|---|---|
| ADC CDMO/CMO | Daiichi Sankyo’s ADC manufacturing expertise creates partnership opportunities for contract manufacturing | High |
| Diagnostic Companion | HER2-low testing requires new diagnostic approaches—opportunity for diagnostic companies | High |
| Emerging Market Distribution | Enhertu and DATROWAY distribution in Southeast Asia, Middle East, Latin America | Medium-High |
| Technology Licensing | DXd platform technology licensing for non-competing therapeutic areas | Medium |
| Clinical Trial Sites | Japan-based clinical trial site partnerships for global Phase 3 programs | Medium |
For Healthcare Providers and Institutions
- HER2 testing infrastructure: The Enhertu-driven shift to HER2-low/ultralow testing requires updated pathology workflows globally
- ADC treatment centers: Specialized oncology centers with ADC administration expertise are in growing demand
- Real-world evidence partnerships: Collaboration opportunities for post-market surveillance and outcomes research
11. Outlook and Strategic Priorities
FY2025–2030 Strategic Targets
| Target | FY2025 | By 2030 |
|---|---|---|
| Revenue | ¥2 trillion | Significant growth beyond ¥2T |
| Approved ADCs | 2 (Enhertu + DATROWAY) | 4+ (adding I-DXd and R-DXd) |
| Enhertu Indications | 8+ FDA approvals | 10+ (including early-stage breast cancer) |
| DATROWAY Indications | 2 (breast + lung) | 4+ (adding TNBC, urothelial) |
| Vision | “Global Pharma Innovator” | “Innovative Global Healthcare Company” |
Key Catalysts to Watch
- July 2026: PDUFA date for Enhertu in early breast cancer (DESTINY-Breast05)
- Q2 2026: FDA action on DATROWAY for triple-negative breast cancer
- 2026–2027: Phase 3 readouts for ifinatamab deruxtecan across SCLC, prostate, and esophageal cancers
- Ongoing: Enhertu first-line metastatic breast cancer regulatory submissions
Risks and Challenges
- Pipeline concentration: Heavy dependence on the DXd platform—if safety signals emerge with the DXd payload, the entire franchise could be affected
- Competitive pressure: Over 200 ADC candidates in development globally, with potential for market share erosion
- Manufacturing scale-up: ADC manufacturing is complex and capacity-constrained; meeting global demand remains a challenge
- Pricing pressure: Specialty drug pricing scrutiny in the US and government-mandated price controls in Japan
About This Report
This company research report was produced by the Japonity Research Team for Japonity.com, a platform dedicated to connecting global businesses with Japanese innovation. Our reports provide data-driven analysis of leading Japanese companies for international partners, investors, and business development professionals.
Need Deeper Research?
Japonity offers custom research and business matching services for companies looking to partner with Japanese firms. Whether you need detailed competitive analysis, market entry strategy, or direct introductions to Japanese decision-makers, our bilingual team can help.
Contact us: info@japonity.com | japonity.com
Interested in Japanese business opportunities?
Whether you're looking for technology partners, engineering talent, or market insights — we can help connect you with the right Japanese organizations.
Get in Touch →
